GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-302-30	30 TABLET in 1 BOTTLE (64764-302-30)	2006-07-28
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-302-90	90 TABLET in 1 BOTTLE (64764-302-90)	2006-07-28
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-304-30	30 TABLET in 1 BOTTLE (64764-304-30)	2006-07-28
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-304-90	90 TABLET in 1 BOTTLE (64764-304-90)	2006-07-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

The global pharmaceutical landscape continues to evolve as regulatory agencies and healthcare providers demand high-quality, affordable medications for managing Type 2 Diabetes Mellitus. Two such widely prescribed drugs are Glimepiride and Pioglitazone Hydrochloride, both belonging to the class of oral hypoglycemic agents. Securing reliable suppliers for these medications is crucial for manufacturers, distributors, and healthcare institutions aiming to ensure consistent drug availability and regulatory compliance. This article provides an in-depth analysis of the key suppliers producing Glimepiride and Pioglitazone Hydrochloride, emphasizing global manufacturing hubs, quality standards, and market dynamics.

Overview of Glimepiride and Pioglitazone Hydrochloride

Glimepiride, a sulfonylurea, stimulates insulin secretion from pancreatic beta cells. It is commonly prescribed for long-term management of type 2 diabetes, often in combination with other agents. Pioglitazone Hydrochloride belongs to the thiazolidinedione class, improving insulin sensitivity in peripheral tissues. Both drugs are included in many brand-name formulations and are produced by a range of generic manufacturers globally, necessitating a robust supply chain network.

Global Manufacturing Landscape for Glimepiride

Major Suppliers and Manufacturers

The production of Glimepiride is concentrated primarily in manufacturing hubs located across India, China, Europe, and North America. Indian pharmaceutical companies dominate the market as key suppliers with significant export volumes.

Sun Pharmaceutical Industries Ltd. (India): Among the leading producers, with a substantial export footprint, adhering to strict WHO GMP standards.
Aurobindo Pharma Limited (India): Recognized for its robust API manufacturing capabilities and quality benchmarks.
Cipla Limited (India): Offers high-quality Glimepiride APIs and finished formulations for global markets.
Zhejiang Hailan Pharmaceutical Co., Ltd. (China): A notable supplier supplying APIs conforming to international quality standards.
Teva Pharmaceutical Industries Ltd. (Israel): Major global generic manufacturer, producing Glimepiride formulations for multiple markets.

API Production and Quality Standards

Indian and Chinese manufacturers adhere to stringent quality standards such as WHO GMP, US FDA, and EMA certifications, facilitating global export. Indian firms benefit from cost advantages and a growing reputation for quality assurance, with some APIs undergoing rigorous third-party testing to meet international specifications.

Market Trends and Supply Dynamics

The global demand for generic Glimepiride has surged, driven by the increasing prevalence of Type 2 Diabetes. Supply chain resilience has improved due to diversified manufacturing sources and increased production capacity. Nonetheless, regulatory compliance remains critical to maintaining supply continuity, especially amidst evolving international trade standards.

Global Manufacturing Landscape for Pioglitazone Hydrochloride

Key Suppliers and Production Hubs

Pioglitazone Hydrochloride’s manufacturing is primarily centered in India, China, and some European countries, with an expanding presence in South Korea and Southeast Asia.

Hetero Labs Ltd. (India): A major supplier with extensive API manufacturing capacity, compliant with global standards.
Mitsubishi Tanabe Pharma Corporation (Japan): Produces both the branded and generic versions, with high-quality API output.
Dr. Reddy’s Laboratories (India): Known for producing high-purity Pioglitazone APIs for both domestic and export markets.
Shandong Sanpharm Co., Ltd. (China): Supplies APIs meeting international regulatory requirements.
Sandoz (Novartis) (Switzerland): Offers formulations and APIs, often serving European markets.

Regulatory and Quality Considerations

Manufacturers targeting global markets must meet stringent regulatory approvals, including US FDA, EMA, and WHO certifications. Indian manufacturers have made significant strides in quality assurance, and several APIs have achieved WHO prequalification status, enabling broader distribution.

Market Trends and Supply Factors

The global market for Pioglitazone has seen fluctuations owing to safety concerns, such as associations with bladder cancer, which prompted regulatory reviews. Nonetheless, demand persists, especially in developing countries with limited access to newer medication options. The stability of API supplies depends heavily on regulatory approvals, manufacturing capacity, and geopolitical stability.

Major Players and Competitive Dynamics

Both Glimepiride and Pioglitazone Hydrochloride are supplied by a mix of multinational corporations and reputable regional manufacturers. The competitive landscape is characterized by:

Cost-competitiveness: Indian and Chinese manufacturers typically offer the most economical options.
Regulatory compliance: Suppliers with WHO, US FDA, and EMA approvals hold a distinct advantage in international markets.
Supply chain resilience: Diversified sourcing is critical amid supply disruptions caused by geopolitical tensions, COVID-19 pandemic impacts, and regulatory changes.
Quality assurance: Advanced analytical techniques and rigorous quality controls differentiate leading suppliers.

Risks and Challenges in the Supply Chain

Regulatory changes: Stringent export restrictions or updated compliance requirements can disrupt production.
Quality assurance: Substandard APIs pose risks of recalls and reputational damage.
Intellectual property and patent issues: Although many formulations are generic, patent expirations influence market entry and supply availability.
Raw material availability: Fluctuations in the supply of starting materials affect API production capacity.
Geopolitical factors: Political instability or trade restrictions impact supply chains, especially from key manufacturing regions.

Emerging Trends and Future Outlook

The pharmaceutical supply chain for Glimepiride and Pioglitazone is poised for continuous growth, driven by increasing diabetes prevalence globally, especially in emerging markets. Manufacturers are investing in quality improvements, expanded capacity, and supply chain diversification to mitigate risks. Additionally, regulatory agencies are emphasizing the importance of Good Manufacturing Practices (GMP) and quality control, which influence supplier selection.

The trend toward biosimilars and combination therapies may also impact the demand for these APIs, with potential shifts toward integrated drug formulations. Digital transformation in manufacturing, including automation and real-time quality monitoring, will further enhance supply reliability.

Conclusion

Securing reliable suppliers for Glimepiride and Pioglitazone Hydrochloride remains vital for stakeholders aiming to meet global demand efficiently and safely. Indian manufacturers lead the production of both APIs, supported by Chinese and European players, all operating under strict quality standards necessary for international markets. As the landscape evolves, companies must prioritize regulatory compliance, quality assurance, supply chain resilience, and cost-effectiveness to maintain a competitive edge.

Key Takeaways

India dominates the global supply chain for Glimepiride and Pioglitazone Hydrochloride, with major players like Sun Pharma, Aurobindo, and Dr. Reddy’s.
Quality standards such as WHO GMP, US FDA, and EMA certifications are critical in supplier selection.
Supply chain resilience hinges on diversification, regulatory compliance, and raw material stability.
Regulatory developments and safety profiles influence market demand and supplier operations.
Future growth hinges on technological advancements, capacity expansion, and evolving therapeutic landscapes.

FAQs

1. Are Indian pharmaceutical companies trusted suppliers for Glimepiride and Pioglitazone APIs?
Yes, Indian companies like Sun Pharma, Aurobindo, and Dr. Reddy’s are globally trusted, often holding WHO GMP, US FDA, and EMA approvals, ensuring high-quality API production.

2. What regulatory standards must suppliers meet to export these APIs internationally?
Suppliers must meet standards such as WHO GMP, US FDA approval, EMA certification, and undergo third-party testing to ensure compliance with international quality and safety benchmarks.

3. How does supply chain diversification impact the availability of Glimepiride and Pioglitazone?
Diversification reduces dependency on a single source, mitigating risks of shortages due to geopolitical issues, regulatory changes, or raw material disruptions, thereby ensuring steady supply.

4. What are the main challenges faced by API manufacturers in the production of these drugs?
Key challenges include strict regulatory compliance, maintaining consistent quality, sourcing raw materials, navigating patent and intellectual property issues, and handling supply chain disruptions.

5. What future trends will influence suppliers of these diabetes drugs?
Emerging trends include increased capacity investments, technological innovations like digital manufacturing, stricter regulatory requirements, and shifts toward combination therapies and biosimilars.

References

[1] World Health Organization. "WHO Certification Standards for API Manufacturers." 2022.
[2] U.S. Food and Drug Administration. "Drug Master Files for APIs." 2023.
[3] Indian Pharmaceutical Alliance. "Annual report on API manufacturing capacities." 2022.
[4] European Medicines Agency. "Guidelines for Veterinary and Human API approval." 2023.
[5] MarketWatch. "Global Diabetes Drugs Market Analysis and Trends." 2023.

Suppliers and packagers for generic pharmaceutical drug: GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE